ArticleClinical and experimental medicine2012
Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers.
Article in Clinical and experimental medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 72 citations in OpenAlex.
- Comprehensive analysis of inhibin-β A as a potential biomarker for gastrointestinal tract cancers through bioinformatics approaches.Scientific reports · 2025Article
- PDK1 promotes epithelial ovarian cancer progression by upregulating BGN.Acta biochimica et biophysica Sinica · 2024Article
- Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.Biology direct · 2024Article
- The Landscape of Small Leucine-Rich Proteoglycan Impact on Cancer Pathogenesis with a Focus on Biglycan and Lumican.Cancers · 2023Review
- Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.Cancer science · 2022Article
- Aberrant expression of the extracellular matrix component Biglycan regulated by Hedgehog signalling promotes colorectal cancer cell proliferation.Acta biochimica et biophysica Sinica · 2022Article
- Screening prognostic genes related to leucovorin, fluorouracil, and irinotecan treatment sensitivity by performing co-expression network analysis for colon cancer.Frontiers in genetics · 2022Article
- Expression and the Prognostic Value of Biglycan in Gastric Cancer.Computational and mathematical methods in medicine · 2022Article
- A Necessary Role for Increased Biglycan Expression during L1-Mediated Colon Cancer Progression.International journal of molecular sciences · 2021Article
- Comprehensive Proteomic Analysis of Colon Cancer Tissue Revealed the Reason for the Worse Prognosis of Right-Sided Colon Cancer and Mucinous Colon Cancer at the Protein Level.Current oncology (Toronto, Ont.) · 2021Article
- Mechanical Pressure Driving Proteoglycan Expression in Mammographic Density: a Self-perpetuating Cycle?Journal of mammary gland biology and neoplasia · 2021Review
- Extracellular Matrix Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2021Review
- Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer.Thoracic cancer · 2021Article
- Benchmark of site- and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer.Glycoconjugate journal · 2021Article
- The Extracellular Small Leucine-Rich Proteoglycan Biglycan Is a Key Player in Gastric Cancer Aggressiveness.Cancers · 2021Article
- Article
- Identification of hub genes in colon cancer via bioinformatics analysis.The Journal of international medical research · 2020Article
- Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis.International journal of molecular sciences · 2020Review
- Proteoglycan signaling in tumor angiogenesis and endothelial cell autophagy.Seminars in cancer biology · 2020Review
- BGN/TLR4/NF-B Mediates Epigenetic Silencing of Immunosuppressive Siglec Ligands in Colon Cancer Cells.Cells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biglycan, an extracellular matrix protein, has been implicated in the oncogenesis and cancer development in various types of human cancer. The clinical significance of biglycan in colorectal cancer, however, remains unclear. In the present study, biglycan mRNA expression was analyzed in 110 samples (primary colorectal tumor and matched adjacent normal tissue) derived from 55 patients with colorectal cancer using quantitative real-time RT-PCR. The correlations between biglycan up-regulation and the clinicopathological data were also evaluated. We found that the up-regulation of biglycan occurred in 61.8% (34/55) of colorectal cancer tissues, and biglycan expression in colorectal cancer tissues was markedly higher than that in corresponding normal tissues (P = 0.0264). Moreover, statistical analysis displayed a significant correlation in biglycan up-regulation with poor tumor differentiation (P = 0.009), lymph node metastasis (P = 0.041), and distant metastasis (P = 0.036). However, there was no significant correlation between biglycan up-regulation and other clinicopathological factors (all P > 0.05). In conclusion, biglycan may be a potential marker for the malignancy of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.